サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1794506

筋骨格系薬剤の世界市場

Musculoskeletal Drugs

出版日
ページ情報
英文 286 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.55円
筋骨格系薬剤の世界市場
出版日: 2025年08月20日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 286 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

筋骨格系薬剤の世界市場は2030年までに1,063億米ドルに達する見込み

2024年に831億米ドルと推定される筋骨格系薬剤の世界市場は、分析期間2024-2030年にCAGR 4.2%で成長し、2030年には1,063億米ドルに達すると予測されます。本レポートで分析したセグメントの一つである非ステロイド性抗炎症薬は、CAGR4.4%を記録し、分析期間終了時には467億米ドルに達すると予測されます。疾患修飾性抗リウマチ薬セグメントの成長率は、分析期間中CAGR 3.0%と推定されます。

米国市場は226億米ドル、中国はCAGR 7.7%で成長予測

米国の筋骨格系薬剤市場は2024年に226億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに218億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは7.7%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.7%と3.3%と予測されています。欧州では、ドイツがCAGR 2.4%で成長すると予測されています。

世界の筋骨格系薬剤市場- 主要動向と促進要因のまとめ

なぜ筋骨格系薬剤は慢性疾患管理の中心であり続けるのか？

筋骨格系薬剤は、骨、関節、筋肉、腱、靭帯に影響を及ぼす幅広い症状の治療に不可欠です。例えば、変形性関節症、関節リウマチ、骨粗鬆症、強直性脊椎炎、痛風、筋痙攣などです。人口が高齢化し、座りっぱなしのライフスタイルが一般的になるにつれ、筋骨格系障害の世界の負担は増加の一途をたどっています。これらの疾患はしばしば慢性疼痛、運動能力の低下、身体障害につながるため、薬理学的治療は長期管理およびQOL向上のための重要な要素となっています。

治療レジメンには鎮痛薬、抗炎症薬、コルチコステロイド、疾患修飾性抗リウマチ薬（DMARDs）、筋弛緩薬、骨吸収阻害薬などが含まれます。炎症性疾患や自己免疫疾患では、疾患の進行を遅らせるために免疫抑制療法や生物学的療法が必要となります。変形性関節症などの退行性疾患では、疼痛コントロールと関節機能に重点が置かれます。治療目標が症状の緩和から機能回復や疾患の改善へとシフトするにつれ、より効果的で的を絞った薬剤の選択肢に対する需要が高まっています。

どのような治療法の進歩が筋骨格系薬剤の状況を変えつつあるのか？

生物学的製剤および標的合成DMARDsは、関節リウマチや乾癬性関節炎などの炎症性筋骨格系疾患の治療成績を著しく改善しました。腫瘍壊死因子（TNF）、インターロイキン-6、ヤヌスキナーゼ（JAK）経路を阻害する薬剤は、免疫介在性関節障害と全身性炎症の制御に役立っています。これらの治療法は、最適なコントロールのために、しばしば従来の薬剤と併用され、疾患経過の早期から使用されるようになってきています。

骨粗鬆症では、新しい抗骨吸収薬や同化薬が骨折予防や骨密度の改善に役立っています。RANKリガンドやスクレロスチンを標的とするモノクローナル抗体は、特に高リスク患者や治療不耐性患者において臨床的に受け入れられています。徐放性製剤や月1回または年2回の注射により、アドヒアランスが向上しています。低分子阻害剤、再生化合物、遺伝子ベースの治療法の調査が進行中であり、変性疾患における組織の分解を逆転させたり、筋骨格系の修復をサポートすることを目指しています。

市場需要を形成している患者集団とヘルスケア動向は？

高齢者人口における関節炎、骨粗鬆症、脊椎疾患の有病率の高さから、高齢者が最大のユーザー基盤を占めています。閉経後の女性は、骨の健康製品の主要ユーザー層です。慢性的な腰痛や関節変性に罹患している現役世代も、特に筋骨格系の問題が仕事の生産性や日常機能に影響を及ぼす都市化社会では、持続的な需要に貢献しています。

若年性関節炎や遺伝性筋骨格系疾患を持つ小児や思春期の患者は、専門的な治療プロトコルを必要とします。スポーツ医学では、筋弛緩薬や抗炎症薬が軟部組織の損傷を管理し、回復を促進するために使用されます。ヘルスケアシステムは、早期診断、リスク層別化、理学療法や薬理学的サポートを含む長期的な疾患管理プログラムを推進するようになってきています。一般市民の意識の高まりやセルフケア文化も、市販の鎮痛剤や関節用サプリメントの使用を促しています。

筋骨格系薬剤市場の成長はいくつかの要因によって牽引...

筋骨格系薬剤市場の成長はいくつかの要因によって牽引されています。関節炎、骨粗鬆症、慢性腰痛の罹患率の上昇により、長期的な薬理学的管理の必要性が高まっています。生物学的製剤や標的治療の進歩により、自己免疫疾患や炎症性疾患に対する治療選択肢が改善されます。人口の高齢化と平均寿命の延長により、慢性期医療分野が拡大します。併用療法や長時間作用型製剤の使用が増加し、アドヒアランスと治療成績が向上します。骨と関節の健康に対する一般市民の意識が高まり、診断へのアクセスが改善されたことで、早期介入が促進されます。新規薬剤に対する規制当局の承認と治療ガイドラインの拡大は、世界の市場拡大をさらに後押しします。

セグメント

薬剤クラス（非ステロイド性抗炎症薬、疾患修飾性抗リウマチ薬、鎮痛薬、コルチコステロイド、その他薬剤クラス別）、流通チャネル（病院薬局、小売薬局、オンライン流通チャネル）

調査対象企業の例

  • AbbVie Inc.
  • Acorda Therapeutics
  • Astellas Pharma Inc.
  • Biogen Inc.
  • Boehringer Ingelheim
  • Bristol Myers Squibb Co.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson Services Inc.
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Sanofi S.A.
  • Sorrento Therapeutics Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • UCB S.A.

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP37468

Global Musculoskeletal Drugs Market to Reach US$106.3 Billion by 2030

The global market for Musculoskeletal Drugs estimated at US$83.1 Billion in the year 2024, is expected to reach US$106.3 Billion by 2030, growing at a CAGR of 4.2% over the analysis period 2024-2030. Nonsteroidal Anti-Inflammatory Drugs, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$46.7 Billion by the end of the analysis period. Growth in the Disease Modifying Anti-Rheumatic Drugs segment is estimated at 3.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$22.6 Billion While China is Forecast to Grow at 7.7% CAGR

The Musculoskeletal Drugs market in the U.S. is estimated at US$22.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$21.8 Billion by the year 2030 trailing a CAGR of 7.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.7% and 3.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.4% CAGR.

Global Musculoskeletal Drugs Market - Key Trends & Drivers Summarized

Why Do Musculoskeletal Drugs Remain Central to Chronic Disease Management?

Musculoskeletal drugs are essential for treating a wide range of conditions that affect bones, joints, muscles, tendons, and ligaments. These include osteoarthritis, rheumatoid arthritis, osteoporosis, ankylosing spondylitis, gout, and muscle spasms. As populations age and sedentary lifestyles become more common, the global burden of musculoskeletal disorders continues to grow. These conditions often lead to chronic pain, reduced mobility, and disability, making pharmacological treatment a critical component of long-term management and quality-of-life improvement.

Treatment regimens include analgesics, anti-inflammatory agents, corticosteroids, disease-modifying antirheumatic drugs (DMARDs), muscle relaxants, and bone resorption inhibitors. Inflammatory and autoimmune conditions require immunosuppressive or biologic therapies to slow disease progression. For degenerative conditions such as osteoarthritis, the focus remains on pain control and joint function. As treatment goals shift from symptom relief to functional restoration and disease modification, demand is rising for more effective, targeted drug options.

What Therapeutic Advances Are Transforming the Musculoskeletal Drug Landscape?

Biologic and targeted synthetic DMARDs have significantly improved outcomes in inflammatory musculoskeletal diseases such as rheumatoid arthritis and psoriatic arthritis. Agents that inhibit tumor necrosis factor (TNF), interleukin-6, or Janus kinase (JAK) pathways help control immune-mediated joint damage and systemic inflammation. These therapies are increasingly used earlier in the disease course, often in combination with conventional agents for optimal control.

In osteoporosis, newer antiresorptive and anabolic drugs are offering better fracture prevention and bone density improvement. Monoclonal antibodies targeting RANK ligand or sclerostin have gained clinical acceptance, especially among high-risk or treatment-intolerant patients. Extended-release formulations and once-monthly or biannual injections are improving adherence. Research into small molecule inhibitors, regenerative compounds, and gene-based therapies is underway, aiming to reverse tissue degradation or support musculoskeletal repair in degenerative diseases.

Which Patient Populations and Healthcare Trends Are Shaping Market Demand?

Older adults represent the largest user base due to the high prevalence of arthritis, osteoporosis, and spinal disorders in aging populations. Women post-menopause form a key demographic for bone health products. Working-age individuals affected by chronic back pain or joint degeneration also contribute to sustained demand, particularly in urbanized societies where musculoskeletal issues impact work productivity and daily function.

Pediatric and adolescent patients with juvenile arthritis or genetic musculoskeletal conditions require specialized treatment protocols. In sports medicine, muscle relaxants and anti-inflammatory drugs are used to manage soft tissue injuries and promote recovery. Healthcare systems are increasingly promoting early diagnosis, risk stratification, and long-term disease management programs, including physical therapy and pharmacological support. Rising public awareness and self-care culture are also encouraging over-the-counter use of pain relievers and joint health supplements.

Growth in the Musculoskeletal Drugs Market Is Driven by Several Factors…

Growth in the musculoskeletal drugs market is driven by several factors. Rising incidence of arthritis, osteoporosis, and chronic back pain increases the need for long-term pharmacological management. Advances in biologics and targeted therapies provide improved treatment options for autoimmune and inflammatory disorders. Aging populations and extended life expectancy expand the chronic care segment. Increased use of combination therapies and long-acting formulations improves adherence and treatment outcomes. Greater public awareness of bone and joint health, along with improved diagnostic access, boosts early intervention. Regulatory approvals for novel agents and expanding treatment guidelines further support market expansion globally.

SCOPE OF STUDY:

The report analyzes the Musculoskeletal Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids, Other Drug Classes); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

  • AbbVie Inc.
  • Acorda Therapeutics
  • Astellas Pharma Inc.
  • Biogen Inc.
  • Boehringer Ingelheim
  • Bristol Myers Squibb Co.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson Services Inc.
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Sanofi S.A.
  • Sorrento Therapeutics Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • UCB S.A.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Musculoskeletal Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Burden of Musculoskeletal Disorders Drives Demand for Targeted Drug Therapies
    • Aging Population Worldwide Throws Spotlight on Osteoarthritis, Rheumatoid Arthritis, and Osteoporosis Treatment Needs
    • Advancements in Biologics and Biosimilars Expand Options in Chronic Inflammatory Musculoskeletal Conditions
    • Increasing Incidence of Back Pain and Sports Injuries Spurs Use of Analgesics, NSAIDs, and Muscle Relaxants
    • Pharmaceutical Innovation in Disease-Modifying Agents Strengthens Long-Term Management of Joint Disorders
    • Growth in Orthopedic Surgical Interventions Creates Demand for Postoperative Pain and Inflammation Control
    • Regulatory Approvals of Injectable Therapies and Long-Acting Drug Formulations Improve Patient Compliance
    • Rising Demand for Personalized and Stratified Treatment Approaches Drives Precision Drug Development
    • Improved Access to Specialty Clinics and Rheumatologists Enhances Early Diagnosis and Pharmacological Intervention
    • Integration of Digital Therapeutics and Remote Monitoring Tools Supports Adherence in Long-Term Therapy
    • Increased Use of Nutraceuticals and Adjunct Therapies Promotes Combined Drug and Lifestyle-Based Interventions
    • Global Expansion of Healthcare Coverage and Reimbursement Schemes Promotes Accessibility of Branded and Generic Drugs
    • Growing Awareness of Musculoskeletal Health Among Working Adults Drives Preventive Use of OTC Products
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Musculoskeletal Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Musculoskeletal Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Musculoskeletal Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Nonsteroidal Anti-Inflammatory Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Nonsteroidal Anti-Inflammatory Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Nonsteroidal Anti-Inflammatory Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Disease Modifying Anti-Rheumatic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Disease Modifying Anti-Rheumatic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Disease Modifying Anti-Rheumatic Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Analgesics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Analgesics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Analgesics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Musculoskeletal Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Musculoskeletal Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Musculoskeletal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Musculoskeletal Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Musculoskeletal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • JAPAN
    • Musculoskeletal Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Musculoskeletal Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Musculoskeletal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • CHINA
    • Musculoskeletal Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: China 16-Year Perspective for Musculoskeletal Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: China 16-Year Perspective for Musculoskeletal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • EUROPE
    • Musculoskeletal Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Musculoskeletal Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Musculoskeletal Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Musculoskeletal Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Musculoskeletal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • FRANCE
    • Musculoskeletal Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: France 16-Year Perspective for Musculoskeletal Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: France 16-Year Perspective for Musculoskeletal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • GERMANY
    • Musculoskeletal Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Musculoskeletal Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Musculoskeletal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Musculoskeletal Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Musculoskeletal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Musculoskeletal Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Musculoskeletal Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Musculoskeletal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Musculoskeletal Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for Musculoskeletal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Musculoskeletal Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for Musculoskeletal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Musculoskeletal Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for Musculoskeletal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Musculoskeletal Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Musculoskeletal Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Musculoskeletal Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Musculoskeletal Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Musculoskeletal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Musculoskeletal Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Musculoskeletal Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for Musculoskeletal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • INDIA
    • Musculoskeletal Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: India 16-Year Perspective for Musculoskeletal Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: India 16-Year Perspective for Musculoskeletal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Musculoskeletal Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for Musculoskeletal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Musculoskeletal Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Musculoskeletal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Musculoskeletal Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Musculoskeletal Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Musculoskeletal Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Musculoskeletal Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Musculoskeletal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Musculoskeletal Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Argentina 16-Year Perspective for Musculoskeletal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Musculoskeletal Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Brazil 16-Year Perspective for Musculoskeletal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Musculoskeletal Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Mexico 16-Year Perspective for Musculoskeletal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Musculoskeletal Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 16-Year Perspective for Musculoskeletal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Musculoskeletal Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Musculoskeletal Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Musculoskeletal Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Musculoskeletal Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Musculoskeletal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Musculoskeletal Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Iran 16-Year Perspective for Musculoskeletal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Musculoskeletal Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Israel 16-Year Perspective for Musculoskeletal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Musculoskeletal Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 16-Year Perspective for Musculoskeletal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Musculoskeletal Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: UAE 16-Year Perspective for Musculoskeletal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Musculoskeletal Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 16-Year Perspective for Musculoskeletal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • AFRICA
    • Musculoskeletal Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Musculoskeletal Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 214: Africa 16-Year Perspective for Musculoskeletal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030

IV. COMPETITION